NurExone Biologic Balance Sheet Health
Financial Health criteria checks 6/6
NurExone Biologic has a total shareholder equity of $2.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $3.3M and $717.0K respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$2.39m |
| Equity | US$2.58m |
| Total liabilities | US$717.00k |
| Total assets | US$3.29m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: J90's short term assets ($2.8M) exceed its short term liabilities ($546.0K).
Long Term Liabilities: J90's short term assets ($2.8M) exceed its long term liabilities ($171.0K).
Debt to Equity History and Analysis
Debt Level: J90 is debt free.
Reducing Debt: J90 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: J90 has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: J90 is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.